The Preferred Premedication Order to Prevent Infusion Reactions in Patients with Breast Cancer Receiving Pertuzumab plus Trastuzumab and Docetaxel
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000045181
- Lead Sponsor
- Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Serious drug hypersensitivity 2) Pregnant or lactation women, or women with suspected pregnancy 3) Other any cancer 4) Other severe complications AMI, heart failure, purmonary fibrosis, uncontrolled DM, severe infection and so on 5) Severe mental disorders 6) Active bleeding of digestive tract 7) Serious myeloablation, renal insufficciency, liver failure 8) Diarrhea 9) Active infection 10) Prior treatment with anti-HER2 therapy for breast cancer 11) Metastatic breast cancer 12) Under treatment with continuous systemic steroid, anti-allergic agent, anti-histamine agent, immunosuppresant, and NSAID 13) Not suitable for participating in the study for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method